Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Yang S, Wu S, Zhao Y, Chen G, Zhu B, Li X, Wang K, Shi J, Cang S, Yao W, Fan Y, Fang J, Zhang L, Zhou J, Wu L, Zheng R, Huang M, Pan Y, Yang Z, Sun M, Yu H, Wang D, Huang J, Wang L, Shu Y, Chen Z, Liu C, Li J, Liu J, Sun S, Guo Y, Meng Z, Liu Z, Han Z, Wu G, Lu H, Ma R, Hu S, Zhao G, Zhang L, Liu Z, Xie C, Zhong D, Zhao H, Bi M, Yi S, Guo S, Yi T, Li W, Lin Y, Chen Z, Zhuang Z, Guo Z, Greco M, Wang T, Zhou A, Shi Y. Yang S, et al. Among authors: zheng r. Lung Cancer. 2023 Jun;180:107194. doi: 10.1016/j.lungcan.2023.107194. Epub 2023 Apr 17. Lung Cancer. 2023. PMID: 37163774 Free article.
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Shi Y, Zhao Y, Yang S, Zhou J, Zhang L, Chen G, Fang J, Zhu B, Li X, Shu Y, Shi J, Zheng R, Wang D, Yu H, Huang J, Zhuang Z, Wu G, Zhang L, Guo Z, Greco M, Li X, Zhang Y. Shi Y, et al. Among authors: zheng r. J Thorac Oncol. 2022 May;17(5):708-717. doi: 10.1016/j.jtho.2022.01.015. Epub 2022 Feb 15. J Thorac Oncol. 2022. PMID: 35181498 Free article. Clinical Trial.
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Shi Y, Zhou J, Zhao Y, Zhu B, Zhang L, Li X, Fang J, Shi J, Zhuang Z, Yang S, Wang D, Yu H, Zhang L, Zheng R, Greco M, Wang T. Shi Y, et al. Among authors: zheng r. BMC Med. 2023 Jan 8;21(1):11. doi: 10.1186/s12916-022-02692-8. BMC Med. 2023. PMID: 36617560 Free PMC article. Clinical Trial.
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.
Wang FH, Wang Y, Sun GP, Chen JH, Lin YC, Liu W, Zheng RS, Chen J, Zhang HL, Lan HT, Qi J, Liu YQ, Deng YM, Zhao H, Xiong JP, Xu Q, Jiang WQ, Li YH. Wang FH, et al. Cancer. 2017 Oct 15;123(20):3986-3994. doi: 10.1002/cncr.30845. Epub 2017 Jun 22. Cancer. 2017. PMID: 28640389 Free article. Clinical Trial.
A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.
Sun Y, Shu Y, Liu B, Liu P, Wu C, Zheng R, Zhang X, Zhuang Z, Deng Y, Zheng L, Xu Q, Jiang B, Ouyang X, Gao J, Xu N, Li X, Jiang S, Liang C, Yao Y. Sun Y, et al. Among authors: zheng r, zheng l. Exp Ther Med. 2016 Dec;12(6):4017-4024. doi: 10.3892/etm.2016.3871. Epub 2016 Nov 4. Exp Ther Med. 2016. PMID: 28105133 Free PMC article.
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D, Ba Y, Xiong J, Xu N, Yan Z, Zhuang Z, Yu Z, Wan H, Zhang Y, Deng T, Zheng R, Guo Z, Hu C, Wang M, Yu Z, Yao Y, Meng J. Huang D, et al. Among authors: zheng r. Eur J Cancer. 2013 Sep;49(14):2995-3002. doi: 10.1016/j.ejca.2013.05.021. Epub 2013 Jun 27. Eur J Cancer. 2013. PMID: 23810466 Clinical Trial.
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ, Xiong JP, Xu N, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Deng T, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC, Ba Y. Huang DZ, et al. Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):865-8. doi: 10.3760/cma.j.issn.0253-3766.2012.11.015. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291139 Clinical Trial. Chinese.
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y, Li J, Xu J, Sun Y, Wang L, Cheng Y, Liu W, Sun G, Chen Y, Bai L, Zhang Y, He X, Luo Y, Wang Z, Liu Y, Yao Q, Li Y, Qin S, Hu X, Bi F, Zheng R, Ouyang X. Shi Y, et al. Among authors: zheng r. Cancer Commun (Lond). 2019 May 24;39(1):28. doi: 10.1186/s40880-019-0374-8. Cancer Commun (Lond). 2019. PMID: 31126331 Free PMC article. Clinical Trial.
[A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer].
Zhou Q, Yan X, Ren L, Li L, Qiu M, Yang Y, Luo D, Huang W, Liu L, Chen Z, Meng Z, Wang Y, Fu Q, Xu Y, Yang L, Li M, Li E, Li Y, Yao Y, Zhang X, Liu X, Lu H, Zhang M, Wang X, Yu X, Qin F, Zheng R, Chen Y, Bi M. Zhou Q, et al. Among authors: zheng r. Zhongguo Fei Ai Za Zhi. 2003 Aug 20;6(4):264-7. doi: 10.3779/j.issn.1009-3419.2003.04.05. Zhongguo Fei Ai Za Zhi. 2003. PMID: 21272478 Free article. Chinese.
4,269 results